X4 Pharmaceuticals Inc. logo

X4 Pharmaceuticals Inc. (XFOR)

Market Closed
27 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
1. 83
-0.17
-8.5%
$
10.59M Market Cap
- P/E Ratio
0% Div Yield
965,900 Volume
-0.63 Eps
$ 2
Previous Close
Day Range
1.81 2.08
Year Range
1.81 26.97
Want to track XFOR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 27 days
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G-CSF while maintaining ANC levels in the normal range Data continue to strengthen confidence in potential success of ongoing global, pivotal Phase 3 trial evaluating mavorixafor in primary chronic neutropenia BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the presentation of positive data from its completed Phase 2 trial of mavorixafor in the treatment of certain chronic neutropenic (CN) conditions at the 30th Annual Congress of the European Hematology Association (EHA) in Milan, Italy. “We are very proud to have sponsored this trial – the first of its kind – evaluating an oral agent for the chronic treatment of certain primary chronic neutropenic disorders,” said Christophe Arbet-Engels, M.D.

Globenewswire | 2 weeks ago
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor

Globenewswire | 1 month ago
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026

Globenewswire | 2 months ago
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025.

Globenewswire | 2 months ago
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.

Seekingalpha | 3 months ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites;  full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026

Globenewswire | 3 months ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.

Globenewswire | 3 months ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt

Globenewswire | 4 months ago
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025

Globenewswire | 4 months ago
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties

Globenewswire | 5 months ago
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.

Globenewswire | 7 months ago
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Kristen Kluska - Cantor Edward Tenthoff - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Stephen Willey - Stifel David Bautz - Zacks Operator Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast.

Seekingalpha | 7 months ago
Loading...
Load More